UNIVERSITY OF MICHIGAN

By 2030, 10.8 million Californians will be older adults, prompting focus on aging population. Black experts advocate for African American seniors' inclusion in research and clinical trials, highlighting underrepresentation and disparities in gerontology and Alzheimer's research. Efforts to improve diversity and trust in medical research are crucial for equitable healthcare.

After years of delays, FDA approves Phase 2 of MAPS' study on smoked medical marijuana for PTSD in veterans, funded by Michigan's cannabis tax revenue.

Mural Oncology published data from ARTISTRY-1 trial showing nemvaleukin's tolerability and antitumor activity in advanced solid tumors, including durable responses in platinum-resistant ovarian cancer.

Genprex, Inc. secures exclusive license from University of Michigan for Reqorsa® Gene Therapy in combination with ALK-inhibitors to treat ALK-positive lung cancer, based on positive preclinical data.

Ann Arbor's SEU plans to install solar panels and batteries on residents' properties, selling power at cost. The city aims to use franchise rights to build wires for local power sharing, leveraging a century-old precedent. This opt-in, cost-effective approach avoids new taxes and maintains a cooperative relationship with DTE, focusing on clean, local energy benefits.

Madeline Barron, Ph.D., is the Science Communications Specialist at ASM, holding a Ph.D. from the University of Michigan's Department of Microbiology and Immunology.

Many parents struggle to manage kids' anger, with 70% admitting they sometimes don't handle it well, potentially modeling poor behavior. One in seven parents think their kids get angrier than peers, and 40% report negative consequences from anger. Effective strategies include cool-off activities, physical outlets, and listening. Parents are advised to seek varied sources of advice and praise constructive anger management.

Ascentage Pharma's NDA for lisaftoclax, a Bcl-2 inhibitor for r/r CLL/SLL, was accepted by China's NMPA with Priority Review, potentially making it the first domestically developed Bcl-2 inhibitor in China and the second globally. This follows a Phase II study showing efficacy and safety in Chinese patients with r/r CLL/SLL, addressing a significant unmet need in China where CLL/SLL incidence is rising.

Scientists fear Trump's administration could undermine public health achievements, with Robert F. Kennedy Jr. potentially leading a radical antiestablishment movement. Vaccine mandates, new vaccine approvals, and FDA decisions could be impacted, along with potential mass firings of dissenting scientists. Kennedy and allies advocate for dramatic public health changes, criticizing government agencies for promoting unhealthy practices and dangerous drugs. The potential for significant changes in federal health agencies, including the NIH and CDC, is concerning to many health professionals.